GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

quavonlimab   Click here for help

GtoPdb Ligand ID: 13890

Synonyms: MK-1308 | MK1308
Immunopharmacology Ligand
Compound class: Antibody
Comment: Quavonlimab (MK-1308) is a humanized IgG1 anti-CTLA-4 monoclonal antibody [1]. It blocks the inhibitory CTLA-4/CD80/CD86 immune checkpoint, as a mechanism to reactivate anti-tumour immune surveillance.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Quavonlimab (MK-1308) is in clinical trials to establish safety and efficacy as an adjunctive anti-tumour agent in treatment regimens for various advanced solid tumour types.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03179436 Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) Phase 1/Phase 2 Interventional Merck Sharp & Dohme LLC 1
NCT04895722 Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) Phase 2 Interventional Merck Sharp & Dohme LLC
NCT04740307 Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) Phase 2 Interventional Merck Sharp & Dohme LLC
NCT03516981 A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) Phase 2 Interventional Merck Sharp & Dohme LLC